Ensysce Biosciences, Inc. (ENSC)
ENSC Stock Price Chart
Explore Ensysce Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze ENSC price movements and trends.
ENSC Company Profile
Discover essential business fundamentals and corporate details for Ensysce Biosciences, Inc. (ENSC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Mar 2018
Employees
7.00
Website
https://www.ensysce.comCEO
D. Lynn Kirkpatrick
Description
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
ENSC Financial Timeline
Browse a chronological timeline of Ensysce Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.50, while revenue estimate is $1.90m.
Earnings released on 15 May 2026
EPS came in at -$0.52 surpassing the estimated -$0.73 by +28.77%, while revenue for the quarter reached $1.00m , missing expectations by -47.37%.
Earnings released on 30 Mar 2026
EPS came in at -$0.75 surpassing the estimated -$1.26 by +40.48%, while revenue for the quarter reached $1.90m , beating expectations by +277.76%.
Earnings released on 14 Nov 2025
EPS came in at -$1.29 falling short of the estimated -$0.85 by -51.76%, while revenue for the quarter reached $493.10k , missing expectations by -29.56%.
Earnings released on 13 Aug 2025
EPS came in at -$0.79 surpassing the estimated -$1.02 by +22.55%, while revenue for the quarter reached $1.37m , missing expectations by -1.96%.
Earnings released on 13 May 2025
EPS came in at -$1.39 surpassing the estimated -$3.02 by +53.97%, while revenue for the quarter reached $1.32m .
Earnings released on 10 Mar 2025
EPS came in at -$2.90 falling short of the estimated -$2.74 by -5.84%, while revenue for the quarter reached $1.30m , beating expectations by +432.24%.
Stock split effective on 6 Dec 2024
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Nov 2024
EPS came in at $1.05 surpassing the estimated -$4.50 by +123.33%, while revenue for the quarter reached $3.42m , beating expectations by +1.30k%.
Earnings released on 14 Aug 2024
EPS came in at -$3.30 surpassing the estimated -$5.85 by +43.59%, while revenue for the quarter reached $181.80k , missing expectations by -39.40%.
Earnings released on 10 May 2024
EPS came in at -$8.25 surpassing the estimated -$13.49 by +38.84%, while revenue for the quarter reached $305.72k , missing expectations by -23.57%.
Earnings released on 15 Mar 2024
EPS came in at -$16.94 falling short of the estimated -$12.89 by -31.42%, while revenue for the quarter reached $515.03k , beating expectations by +106.01%.
Earnings released on 9 Nov 2023
EPS came in at -$13.04 surpassing the estimated -$15.89 by +17.94%, while revenue for the quarter reached $435.38k , beating expectations by +11.64%.
Earnings released on 11 Aug 2023
EPS came in at -$14.69 surpassing the estimated -$40.93 by +64.11%, while revenue for the quarter reached $490.47k , missing expectations by -40.91%.
Earnings released on 15 May 2023
EPS came in at -$31.18 surpassing the estimated -$208.55 by +85.05%, while revenue for the quarter reached $789.64k , missing expectations by -16.88%.
Stock split effective on 31 Mar 2023
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Mar 2023
EPS came in at -$273.57 surpassing the estimated -$466.15 by +41.31%, while revenue for the quarter reached $1.43m , beating expectations by +49.27%.
Earnings released on 14 Nov 2022
EPS came in at -$923.31 falling short of the estimated -$539.95 by -71.00%, while revenue for the quarter reached $279.35k , missing expectations by -81.86%.
Stock split effective on 28 Oct 2022
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2022
EPS came in at -$863.91 falling short of the estimated -$755.92 by -14.29%, while revenue for the quarter reached $207.47k , missing expectations by -79.25%.
Earnings released on 12 May 2022
EPS came in at -$719.93 matching the estimated -$719.93, while revenue for the quarter reached $603.10k , missing expectations by -49.74%.
Earnings released on 31 Mar 2022
EPS came in at -$1.62k falling short of the estimated $323.97 by -600.00%, while revenue for the quarter reached $1.64m , beating expectations by +104.38%.
Earnings released on 15 Nov 2021
EPS came in at -$2.56k , while revenue for the quarter reached $1.20m .
Earnings released on 16 Aug 2021
EPS came in at -$215.98 , while revenue for the quarter reached $444.52k .
ENSC Stock Performance
Access detailed ENSC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
